Sartorius AG/ADR (SOAGY) Stock
SOAGY has an Alpha Score of 31 out of 100 (poor), computed on Nov 8, 2026 from 3 of 4 sub-scores. 1 member of Congress disclosed 1 trade in SOAGY since 2023: 0 purchases and 1 sale, most recently Daniel Goldman (sale, Jul 10, 2023). Its trailing P/E ratio is 90.9 and its net margin 5.5% (key statistics as of Nov 7, 2026).
What is SOAGY's Alpha Score?
How it works →Alpha Score of 31 reflects weak overall profile with weak momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Sartorius AG/ADR (SOAGY)?
Most recent: Daniel Goldman (sale, Jul 10, 2023); records start Jul 10, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-07-10 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 6, 2026.
See all SOAGY political trades →What are SOAGY's key statistics?
Key statistics as of Nov 7, 2026
How does SOAGY's valuation compare with the Healthcare sector?
| Metric | SOAGY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 90.9 | 29.7 | 114 |
| Net margin | 5.48% | 3.62% | 174 |
| Return on equity | 7.18% | 2.96% | 200 |
| Dividend yield (payers) | 0.62% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
SOAGY price chart
Powered by TradingViewWhat does Sartorius AG/ADR do?
Sartorius AG Unsponsored ADR represents an American Depositary Receipt for Sartorius AG, a global pharmaceutical and laboratory equipment supplier. The primary function of this ADR is to allow U.S. investors easy access to Sartorius AG's shares, which are traded on exchanges outside the United States. Sartorius AG is renowned in the life sciences and biopharmaceutical industries, with a focus on providing innovative solutions that enhance complex manufacturing processes. The company offers a diverse range of products, including laboratory instruments, consumables, and innovative technology solutions that are integral to drug research and biopharmaceutical production. The unsponsored nature of this ADR means it is issued by a depositary bank without direct involvement from Sartorius AG itself. This ADR plays a significant role in expanding Sartorius AG's investor base by allowing U.S. investors to participate in the company's growth and benefit from the advancements in healthcare and biotechnology fields. It contributes to greater global visibility and liquidity of Sartorius AG’s offerings in international financial markets.